Werewolf Therapeutics Stock (NASDAQ:HOWL)

Forecast Ownership Financials Chart

Previous Close

$0.81

52W Range

$0.53 - $2.38

50D Avg

$0.80

200D Avg

$1.08

Market Cap

$40.34M

Avg Vol (3M)

$386.62K

Beta

0.54

Div Yield

HOWL Company Profile

Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of relapsed or refractory advanced or metastatic solid tumors or lymphoma. The company is also developing WTX-613, a conditionally activated interferon alpha INDUKINE molecule for the treatment of solid tumors and hematologic malignancies. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Country

Employees

IPO Date

Apr 30, 2021

Website

HOWL Performance

HOWL Financial Summary

	Dec 25	Dec 24	Dec 23
Revenue	-	$1.89M	$19.94M
Operating Income	$-60.68M	$-73.59M	$-40.50M
Net Income	$-60.82M	$-70.52M	$-37.37M
EBITDA	$-59.04M	$-64.05M	$-32.47M
Basic EPS	$-1.32	$-1.63	$-1.05
Diluted EPS	$-1.33	$-1.63	$-1.05

Fiscal year ends in Dec 25 | Currency in USD

Peer Comparison

Ticker	Company
OSTX	OS Therapies Incorporated
LITS	Lite Strategy, Inc.
CUE	Cue Biopharma, Inc.
INMB	INmune Bio, Inc.
OTLK	Outlook Therapeutics, Inc.
SPRB	Spruce Biosciences, Inc.
NRXP	NRx Pharmaceuticals, Inc.
IOBT	IO Biotech, Inc.
ACET	Adicet Bio, Inc.